101
|
Feng JW, Wu WX, Qi GF, Hong LZ, Hu J, Liu SY, Jiang Y, Ye J. Nomograms based on sonographic and clinicopathological characteristics to predict lateral lymph node metastasis in classic papillary thyroid carcinoma. J Endocrinol Invest 2022; 45:2043-2057. [PMID: 35809195 DOI: 10.1007/s40618-022-01825-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/23/2021] [Accepted: 05/08/2022] [Indexed: 11/28/2022]
Abstract
BACKGROUND Lateral lymph node metastasis (LLNM) has been considered a risk factor of recurrence in papillary thyroid cancer (PTC). Preoperative detecting LLNM accurately is difficult. Solitary lateral lymph node metastasis is a special type of LLNM. We aimed to develop nomograms for predicting LLNM and multiple lateral lymph node metastasis (MLLNM). METHODS We retrospectively retrieved 528 classic PTC patients that underwent surgery between March 2019 and May 2020. Sonographic and clinicopathological features were collected. Risk factors of LLNM and MLLNM were determined by univariate and multivariate analysis. Nomograms for predicting LLNM and MLLNM were developed. RESULTS LLNM was independently associated with tumor size, the number of foci, location, margin, central lymph node metastasis, and lymph node ratio. Independent predictors of MLLNM were age, margin, and the number of metastatic lymph nodes in central compartment. By using above variables, we constructed nomograms for predicting LLNM and MLLNM, with area under curves of 0.864 and 0.748, respectively. CONCLUSION Through these accurate and easy-to-use nomograms, we can detect the risk of residual LLNM postoperatively for classic PTC patients who did not receive lateral neck dissection and provide an individualized plan for postoperative management of classic PTC patients.
Collapse
|
102
|
Hu J, Zhong LZ, Li TT, Jia QY, Li HM. [Study of risk factors of postherpetic neuralgia]. ZHONGHUA YI XUE ZA ZHI 2022; 102:3181-3185. [PMID: 36319171 DOI: 10.3760/cma.j.cn112137-20220601-01213] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/16/2023]
Abstract
Objective: To analyze the clinical features and risk factors of herpes zoster and the risk factors of postherpetic neuralgia (PHN). Methods: A total of 2 840 patients diagnosed with herpes zoster in Peking University People's Hospital from January 2021 to April 2022 were included. The patients with herpes zoster were aged (59±16), and of which 1 314 (46.3%) patients were male. The patients were divided into PHN group and non-PHN group according to whether the patients with herpes zoster developed PHN. And there were 442 (15.6%) patients developed PHN aged (68±12), and of which 189 (42.8%) were male. The information and medical history of PHN group and non-PHN group were collected. The information of the use of glucocorticoids, immunosuppressive agents, biological agents and targeted medicine within 2 months before herpes zoster occurred, history of surgery within 6 months before herpes zoster occurred, and the duration of PHN were collected. Logistic regression analysis was used to analyze the risk factors of PHN. Results: Out of 2 840 patients, 2 056 (72.4%) with herpes zoster aged 50 years and above. Intercostal nerves was mostly involved in patients with herpes zoster, with a total of 1 532(53.9%). Hypertension (465 cases, 16.4%) accounted for the highest number of patients with chronic diseases, followed by diabetes (337 cases, 11.9%) and coronary heart disease (283 cases, 10.0%). Rheumatoid arthritis (41 cases, 1.4%) accounted for the highest number of patients with connective tissue diseases, followed by Sjogren's syndrome (31 cases, 1.1%), systemic lupus erythematosus (28 cases, 1.0%). Logistic regression analysis showed that age≥50 years old (OR: 4.581; 95%CI: 3.131-6.705),lesion on the upper limb and shoulder (OR: 1.858; 95%CI: 1.129-3.059), hypertension (OR: 1.963; 95%CI: 1.513-2.546) and immunosuppressive treatments (OR: 2.170; 95%CI: 1.254-3.753) were independent risk factors for PHN (all P<0.05). Conclusions: Herpes zoster mostly occurs in people aged 50 and above, and mainly affected intercostal nerves. The most common complications are hypertension and rheumatoid arthritis. Age≥50, lesion on upper limbs and shoulders, hypertension, and immunosuppressive treatments may be independent risk factors of PHN.
Collapse
|
103
|
Li Z, Yu X, Guo H, Lee T, Hu J. A maximum-type microbial differential abundance test with application to high-dimensional microbiome data analyses. Front Cell Infect Microbiol 2022; 12:988717. [PMID: 36389165 PMCID: PMC9650337 DOI: 10.3389/fcimb.2022.988717] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/07/2022] [Accepted: 10/04/2022] [Indexed: 12/03/2022] Open
Abstract
Background High-throughput metagenomic sequencing technologies have shown prominent advantages over traditional pathogen detection methods, bringing great potential in clinical pathogen diagnosis and treatment of infectious diseases. Nevertheless, how to accurately detect the difference in microbiome profiles between treatment or disease conditions remains computationally challenging. Results In this study, we propose a novel test for identifying the difference between two high-dimensional microbiome abundance data matrices based on the centered log-ratio transformation of the microbiome compositions. The test p-value can be calculated directly with a closed-form solution from the derived asymptotic null distribution. We also investigate the asymptotic statistical power against sparse alternatives that are typically encountered in microbiome studies. The proposed test is maximum-type equal-covariance-assumption-free (MECAF), making it widely applicable to studies that compare microbiome compositions between conditions. Our simulation studies demonstrated that the proposed MECAF test achieves more desirable power than competing methods while having the type I error rate well controlled under various scenarios. The usefulness of the proposed test is further illustrated with two real microbiome data analyses. The source code of the proposed method is freely available at https://github.com/Jiyuan-NYU-Langone/MECAF. Conclusions MECAF is a flexible differential abundance test and achieves statistical efficiency in analyzing high-throughput microbiome data. The proposed new method will allow us to efficiently discover shifts in microbiome abundances between disease and treatment conditions, broadening our understanding of the disease and ultimately improving clinical diagnosis and treatment.
Collapse
|
104
|
Young JT, Goers AJ, Brown DM, Dennis ML, Lehr K, Wei C, Menyuk CR, Hu J. Tradeoff between the Brillouin and transverse mode instabilities in Yb-doped fiber amplifiers. OPTICS EXPRESS 2022; 30:40691-40703. [PMID: 36298999 DOI: 10.1364/oe.472829] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/10/2022] [Accepted: 09/06/2022] [Indexed: 06/16/2023]
Abstract
The Brillouin instability (BI) due to stimulated Brillouin scattering (SBS) and the transverse (thermal) mode instability (TMI) due to stimulated thermal Rayleigh scattering (STRS) limit the achievable power in high-power lasers and amplifiers. The pump power threshold for BI increases as the core diameter increases, but the threshold for TMI may decrease as the core diameter increases. In this paper, we use a multi-time-scale approach to simultaneously model BI and TMI, which gives us the ability to find the fiber diameter with the highest power threshold. We formulate the equations to compare the thresholds of the combined and individual TMI and BI models. At the pump power threshold and below, there is a negligible difference between the full and individual models, as BI and TMI are not strong enough to interact with each other. The highest pump threshold occurs at the optimal core size of 43 µm for the simple double-clad geometry that we considered. We found that both effects contribute equally to the threshold, and the full BI and TMI model yields a similar threshold as the BI or TMI model alone. However, once the reflectivity is sufficiently large, we find in the full BI and TMI model that BI may trigger TMI and reduce the TMI threshold to a value lower than is predicted in simulations with TMI alone. This result cannot be predicted by models that consider BI and TMI separately. Our approach can be extended to more complex geometries and used for their optimization.
Collapse
|
105
|
Awonusi BO, Li J, Li H, Wang Z, Hu J, Yang K, Zhao J. In vivo study on Heparin/poly-L-lysine-copper coating for surface functionalization of ureteral stent. Regen Biomater 2022; 9:rbac083. [PMID: 36338173 PMCID: PMC9629973 DOI: 10.1093/rb/rbac083] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2022] [Revised: 10/01/2022] [Accepted: 10/18/2022] [Indexed: 11/25/2022] Open
Abstract
Polyurethane (PU) ureteral stents are used in clinics to maintain the ureteral patency. Due to biofilm formation and encrustation complications, long-term clinical usage has been limited. It is therefore necessary to develop an effective response to this unmet medical need. A heparin/poly-l-lysine/copper (NPs) coating was developed in our previous work that showed the effect of preventing infection and encrustation in vitro. In this work, a further study was conducted by grafting NPs on clinical ureteral stents that then were implanted into the infectious bladders of Wistar rats to investigate the effects of nanoparticles on bacterial growth and crystal deposition in vivo. It was found that decreased numbers of adherent microbes, urease amount splitting by bacteria, and deposited crystals were observed on the NPs stents with significant differences in comparison with PU stents. Besides, histological analysis showed that the NPs stents decreased the host tissue inflammation in close relation to the decrease biofilm formation and encrustation after 28 days of implantation.
Collapse
|
106
|
Sorensen C, Lehmann E, Holder C, Hu J, Krishnan A, Münzel T, Mb R, Rn S. Reducing the health impacts of ambient air pollution. BMJ 2022; 379:e069487. [PMID: 36223913 DOI: 10.1136/bmj-2021-069487] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
|
107
|
Pillai PM, Mallory N, Pierro J, Saliba J, Newman D, Hu J, Bhatla T, Raetz E, Carroll WL, Evensen NA. Activation of the mitogen-activated protein kinase-extracellular signal-regulated kinase pathway in childhood B-cell acute lymphoblastic leukemia. Pediatr Blood Cancer 2022; 69:e29771. [PMID: 35593589 DOI: 10.1002/pbc.29771] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/22/2022] [Revised: 04/04/2022] [Accepted: 04/22/2022] [Indexed: 11/09/2022]
Abstract
RAS mutations are frequently observed in childhood B-cell acute lymphoblastic leukemia (B-ALL) and previous studies have yielded conflicting results as to whether they are associated with a poor outcome. We and others have demonstrated that the mitogen-activated protein kinase-extracellular signal-regulated kinase (MAPK) pathway can be activated through epigenetic mechanisms in the absence of RAS pathway mutations. Herein, we examined whether MAPK activation, as determined by measuring phosphorylated extracellular signal-regulated kinase (pERK) levels in 80 diagnostic patient samples using phosphoflow cytometry, could be used as a prognostic biomarker for pediatric B-ALL. The mean fluorescence intensity of pERK (MFI) was measured at baseline and after exogenous stimulation with or without pretreatment with the mitogen-activated protein kinase kinase (MEK) inhibitor trametinib. Activation levels (MFI stimulated/MFI baseline) ranged from 0.76 to 4.40 (median = 1.26), and inhibition indexes (MFI stimulated/MFI trametinib stimulated) ranged from 0.439 to 5.640 (median = 1.30), with no significant difference between patients with wildtype versus mutant RAS for either. Logistic regression demonstrated that neither MAPK activation levels nor RAS mutation status at diagnosis alone or in combination was prognostic of outcome. However, 35% of RAS wildtype samples showed MAPK inhibition indexes greater than the median, thus raising the possibility that therapeutic strategies to inhibit MAPK activation may not be restricted to patients whose blasts display Ras pathway defects.
Collapse
|
108
|
Hu J, Li L, Chen W. [Research advances on influencing factors and intervention strategies of pediatric burns]. ZHONGHUA SHAO SHANG YU CHUANG MIAN XIU FU ZA ZHI 2022; 38:883-886. [PMID: 36177596 DOI: 10.3760/cma.j.cn501120-20210830-00295] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 06/16/2023]
Abstract
Burns not only affect children's physiology and psychology, but also bring a burden to their families and society, which can be prevented to a large extent. By introducing the epidemiological characteristics and current disease burden of pediatric burns, and combining them with the Haddon matrix, this paper reviews the progresses on the influencing factors and interventional measures of pediatric burns from three aspects: host, injury factors, and environment. It aims to provide a theoretical basis for the developments of burn risk assessment tools suitable for Chinese pediatric burns and to provide a reference for the formulation of related comprehensive and multi-level intervention measures.
Collapse
|
109
|
Hu J, Ding N, Chen Y, Liu J, Zhou J, Xu X, Bao H, Song Y, Zhang D, Shao Y, Zhang Y. 1011P MET and NF2 alterations confer early resistance to first-line alectinib treatment in ALK-rearranged non-small cell lung cancer. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.1137] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
110
|
Wu F, Liu J, Hu C, Liu J, Zhao W, Wu Y, Xu Y, Hu J, Xiao L, Liu X, Pan Y, Zeng Y, Shi S, Peng Y, Jiang Y. EP01.07-005 Combined Diffusion-Weighted Imaging and Dynamic Contrast-Enhanced MRI for Diagnosing Indeterminate Pulmonary Nodules. J Thorac Oncol 2022. [DOI: 10.1016/j.jtho.2022.07.326] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
111
|
Hu J, Xue S, Mercolli L, Hasan S, Rominger A, Afshar-Oromieh A, Shi K. 1419P Radiobiological parameters for the assessment of 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.1905] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
112
|
Liang W, Xu E, Zhao J, Wang M, Zhang Z, Liang Y, Cheng C, Wang G, Zhong C, Liang Z, Chen X, Zheng B, Huang Y, Hu J, Xu L, Xie M, Liang N, Xu S, Liu J, Wei L, Peng Z, Zhang G, Zhang S, Xu S, He J. EP05.02-009 Aumolertinib Versus Erlotinib/Chemotherapy for Neoadjuvant Treatment of Stage IIIA EGFR-mutant NSCLC (ANSWER). J Thorac Oncol 2022. [DOI: 10.1016/j.jtho.2022.07.491] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
113
|
Qing Z, Zhao J, Gao B, Wang M, Chang J, Hu J, Li J, Zhang J, Zhang Q, Fei C, Wu YL. 1187TiP Phase III study of tislelizumab (TIS) with sitravatinib versus chemotherapy (chemo) in patients with locally advanced/metastatic non-small cell lung cancer (NSCLC) previously treated with chemo and an anti-programmed cell death protein 1/ligand 1 (PD-[L]1) antibody. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.1310] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
114
|
Liu FF, Chen JY, Zhang H, Wang YD, Jiang JZ, Hu J, Zhu ZF, Chen Y, Chu Q. [Incidence and risk factors of thromboembolism in patients with lung cancer receiving immunotherapy]. ZHONGHUA YI XUE ZA ZHI 2022; 102:2489-2494. [PMID: 36008318 DOI: 10.3760/cma.j.cn112137-20220124-00175] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/15/2023]
Abstract
Objective: To evaluate the incidence of thromboembolism in a cohort of patients with lung cancer who received immune checkpoint inhibitors (ICIs), and explore relevant clinical risk factors. Methods: We retrospectively collected and analyzed the clinical data of patients with confirmed primary lung cancer and treated with ICIs between March 2018 and June 2021 at three hospitals in China (Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology, Fudan University Shanghai Cancer Center and Zhongshan Hospital of Fudan University). The cumulative incidence and risk factors of thromboembolism in these patients were analyzed using a competitive risk model. Results: A total of 804 patients were enrolled, there were 623 males and 181 females, with a median age of 59 years (ranged 28-86 years). Of these, 62 patients encountered 65 thromboembolic events, including 51 venous thromboembolism events (VTE) and 14 arterial thromboembolism events. The cumulative incidence of thromboembolism events at 3, 6, 12 and 24 months were 4.3%, 6.1%, 10.1% and 16.8%, respectively. And the cumulative incidence of venous thromboembolism events at 3, 6, 12 and 24 months were 3.4%, 4.7%, 9.0% and 13.3%, respectively. Multivariate analysis showed that history of thromboembolism (HR=6.345, 95%CI: 2.917-13.802,P<0.001),liver metastasis (HR=2.249, 95%CI: 1.123-4.502,P=0.022) and peripherally inserted central venous catheter (HR=3.674, 95%CI: 1.751-7.712, P<0.001) were independent risk factors for venous thromboembolism during ICIs therapy in patients with lung cancer. Conclusions: Patients with lung cancer under ICIs therapy are at high risk of thromboembolism. And history of thromboembolism, liver metastasis and peripherally inserted central venous catheter are risk factors of venous thromboembolism.
Collapse
|
115
|
Aaij R, Abdelmotteleb ASW, Abellán Beteta C, Abudinén F, Ackernley T, Adeva B, Adinolfi M, Afsharnia H, Agapopoulou C, Aidala CA, Aiola S, Ajaltouni Z, Akar S, Albrecht J, Alessio F, Alexander M, Alfonso Albero A, Aliouche Z, Alkhazov G, Alvarez Cartelle P, Amato S, Amey JL, Amhis Y, An L, Anderlini L, Andersson M, Andreianov A, Andreotti M, Andreou D, Ao D, Archilli F, Artamonov A, Artuso M, Arzymatov K, Aslanides E, Atzeni M, Audurier B, Bachmann S, Bachmayer M, Back JJ, Baladron Rodriguez P, Balagura V, Baldini W, Baptista de Souza Leite J, Barbetti M, Barlow RJ, Barsuk S, Barter W, Bartolini M, Baryshnikov F, Basels JM, Bassi G, Batsukh B, Battig A, Bay A, Beck A, Becker M, Bedeschi F, Bediaga I, Beiter A, Belavin V, Belin S, Bellee V, Belous K, Belov I, Belyaev I, Bencivenni G, Ben-Haim E, Berezhnoy A, Bernet R, Berninghoff D, Bernstein HC, Bertella C, Bertolin A, Betancourt C, Betti F, Bezshyiko I, Bhasin S, Bhom J, Bian L, Bieker MS, Biesuz NV, Bifani S, Billoir P, Biolchini A, Birch M, Bishop FCR, Bitadze A, Bizzeti A, Bjørn M, Blago MP, Blake T, Blanc F, Blusk S, Bobulska D, Boelhauve JA, Boente Garcia O, Boettcher T, Boldyrev A, Bondar A, Bondar N, Borghi S, Borisyak M, Borsato M, Borsuk JT, Bouchiba SA, Bowcock TJV, Boyer A, Bozzi C, Bradley MJ, Braun S, Brea Rodriguez A, Brodzicka J, Brossa Gonzalo A, Brundu D, Buonaura A, Buonincontri L, Burke AT, Burr C, Bursche A, Butkevich A, Butter JS, Buytaert J, Byczynski W, Cadeddu S, Cai H, Calabrese R, Calefice L, Cali S, Calladine R, Calvi M, Calvo Gomez M, Camargo Magalhaes P, Campana P, Campora Perez DH, Campoverde Quezada AF, Capelli S, Capriotti L, Carbone A, Carboni G, Cardinale R, Cardini A, Carli I, Carniti P, Carus L, Carvalho Akiba K, Casais Vidal A, Caspary R, Casse G, Cattaneo M, Cavallero G, Celani S, Cerasoli J, Cervenkov D, Chadwick AJ, Chapman MG, Charles M, Charpentier P, Chavez Barajas CA, Chefdeville M, Chen C, Chen S, Chernov A, Chernyshenko S, Chobanova V, Cholak S, Chrzaszcz M, Chubykin A, Chulikov V, Ciambrone P, Cicala MF, Cid Vidal X, Ciezarek G, Clarke PEL, Clemencic M, Cliff HV, Closier J, Cobbledick JL, Coco V, Coelho JAB, Cogan J, Cogneras E, Cojocariu L, Collins P, Colombo T, Congedo L, Contu A, Cooke N, Coombs G, Corredoira I, Corti G, Costa Sobral CM, Couturier B, Craik DC, Crkovská J, Cruz Torres M, Currie R, Da Silva CL, Dadabaev S, Dai L, Dall'Occo E, Dalseno J, D'Ambrosio C, Danilina A, d'Argent P, Dashkina A, Davies JE, Davis A, De Aguiar Francisco O, De Boer J, De Bruyn K, De Capua S, De Cian M, De Freitas Carneiro Da Graca U, De Lucia E, De Miranda JM, De Paula L, De Serio M, De Simone D, De Simone P, De Vellis F, de Vries JA, Dean CT, Debernardis F, Decamp D, Dedu V, Del Buono L, Delaney B, Dembinski HP, Denysenko V, Derkach D, Deschamps O, Dettori F, Dey B, Di Cicco A, Di Nezza P, Didenko S, Dieste Maronas L, Dijkstra H, Ding S, Dobishuk V, Dong C, Donohoe AM, Dordei F, Dos Reis AC, Douglas L, Dovbnya A, Downes AG, Dudek MW, Dufour L, Duk V, Durante P, Durham JM, Dutta D, Dziurda A, Dzyuba A, Easo S, Egede U, Egorychev V, Eidelman S, Eisenhardt S, Ek-In S, Eklund L, Ely S, Ene A, Epple E, Escher S, Eschle J, Esen S, Evans T, Falcao LN, Fan Y, Fang B, Farry S, Fazzini D, Féo M, Fernandez Prieto A, Fernez AD, Ferrari F, Ferreira Lopes L, Ferreira Rodrigues F, Ferreres Sole S, Ferrillo M, Ferro-Luzzi M, Filippov S, Fini RA, Fiorini M, Firlej M, Fischer KM, Fitzgerald DS, Fitzpatrick C, Fiutowski T, Fkiaras A, Fleuret F, Fontana M, Fontanelli F, Forty R, Foulds-Holt D, Franco Lima V, Franco Sevilla M, Frank M, Franzoso E, Frau G, Frei C, Friday DA, Fu J, Fuehring Q, Gabriel E, Galati G, Gallas Torreira A, Galli D, Gambetta S, Gan Y, Gandelman M, Gandini P, Gao Y, Garau M, Garcia Martin LM, Garcia Moreno P, García Pardiñas J, Garcia Plana B, Garcia Rosales FA, Garrido L, Gaspar C, Geertsema RE, Gerick D, Gerken LL, Gersabeck E, Gersabeck M, Gershon T, Gerstel D, Giambastiani L, Gibson V, Giemza HK, Gilman AL, Giovannetti M, Gioventù A, Gironella Gironell P, Giugliano C, Giza MA, Gizdov K, Gkougkousis EL, Gligorov VV, Göbel C, Golobardes E, Golubkov D, Golutvin A, Gomes A, Gomez Fernandez S, Goncalves Abrantes F, Goncerz M, Gong G, Gorbounov P, Gorelov IV, Gotti C, Grabowski JP, Grammatico T, Granado Cardoso LA, Graugés E, Graverini E, Graziani G, Grecu A, Greeven LM, Grieser NA, Grillo L, Gromov S, Gruberg Cazon BR, Gu C, Guarise M, Guittiere M, Günther PA, Gushchin E, Guth A, Guz Y, Gys T, Hadavizadeh T, Haefeli G, Haen C, Haimberger J, Haines SC, Halewood-Leagas T, Halvorsen MM, Hamilton PM, Hammerich JP, Han Q, Han X, Hansen EB, Hansmann-Menzemer S, Harnew N, Harrison T, Hasse C, Hatch M, He J, Hecker M, Heijhoff K, Heinicke K, Henderson RDL, Hennequin AM, Hennessy K, Henry L, Heuel J, Hicheur A, Hill D, Hilton M, Hollitt SE, Hou R, Hou Y, Hu J, Hu J, Hu W, Hu X, Huang W, Huang X, Hulsbergen W, Hunter RJ, Hushchyn M, Hutchcroft D, Hynds D, Ibis P, Idzik M, Ilin D, Ilten P, Inglessi A, Iniukhin A, Ishteev A, Ivshin K, Jacobsson R, Jage H, Jakobsen S, Jans E, Jashal BK, Jawahery A, Jevtic V, Jiang X, John M, Johnson D, Jones CR, Jones TP, Jost B, Jurik N, Juszczak I, Kandybei S, Kang Y, Karacson M, Karpenkov D, Karpov M, Kautz JW, Keizer F, Keller DM, Kenzie M, Ketel T, Khanji B, Kharisova A, Kholodenko S, Kirn T, Kirsebom VS, Kitouni O, Klaver S, Kleijne N, Klimaszewski K, Kmiec MR, Koliiev S, Kondybayeva A, Konoplyannikov A, Kopciewicz P, Kopecna R, Koppenburg P, Korolev M, Kostiuk I, Kot O, Kotriakhova S, Kozachuk A, Kravchenko P, Kravchuk L, Krawczyk RD, Kreps M, Kretzschmar S, Krokovny P, Krupa W, Krzemien W, Kubat J, Kucewicz W, Kucharczyk M, Kudryavtsev V, Kuindersma HS, Kunde GJ, Kvaratskheliya T, Lacarrere D, Lafferty G, Lai A, Lampis A, Lancierini D, Lane JJ, Lane R, Lanfranchi G, Langenbruch C, Langer J, Lantwin O, Latham T, Lazzari F, Le Gac R, Lee SH, Lefèvre R, Leflat A, Legotin S, Leroy O, Lesiak T, Leverington B, Li H, Li K, Li P, Li S, Li Y, Li Z, Liang X, Lin C, Lin T, Lindner R, Lisovskyi V, Litvinov R, Liu G, Liu H, Liu Q, Liu S, Lobo Salvia A, Loi A, Lollini R, Lomba Castro J, Longstaff I, Lopes JH, López Soliño S, Lovell GH, Lu Y, Lucarelli C, Lucchesi D, Luchuk S, Lucio Martinez M, Lukashenko V, Luo Y, Lupato A, Luppi E, Lupton O, Lusiani A, Lyu X, Ma L, Ma R, Maccolini S, Machefert F, Maciuc F, Macko V, Mackowiak P, Maddrell-Mander S, Madhan Mohan LR, Maev O, Maevskiy A, Maisuzenko D, Majewski MW, Malczewski JJ, Malde S, Malecki B, Malinin A, Maltsev T, Malygina H, Manca G, Mancinelli G, Manuzzi D, Manzari CA, Marangotto D, Maratas J, Marchand JF, Marconi U, Mariani S, Marin Benito C, Marinangeli M, Marks J, Marshall AM, Marshall PJ, Martelli G, Martellotti G, Martinazzoli L, Martinelli M, Martinez Santos D, Martinez Vidal F, Massafferri A, Materok M, Matev R, Mathad A, Matiunin V, Matteuzzi C, Mattioli KR, Mauri A, Maurice E, Mauricio J, Mazurek M, McCann M, Mcconnell L, Mcgrath TH, Mchugh NT, McNab A, McNulty R, Mead JV, Meadows B, Meier G, Melnychuk D, Meloni S, Merk M, Merli A, Meyer Garcia L, Mikhasenko M, Milanes DA, Millard E, Milovanovic M, Minard MN, Minotti A, Mitchell SE, Mitreska B, Mitzel DS, Mödden A, Mohammed RA, Moise RD, Mokhnenko S, Mombächer T, Monroy IA, Monteil S, Morandin M, Morello G, Morello MJ, Moron J, Morris AB, Morris AG, Mountain R, Mu H, Muheim F, Mulder M, Müller K, Murphy CH, Murray D, Murta R, Muzzetto P, Naik P, Nakada T, Nandakumar R, Nanut T, Nasteva I, Needham M, Neri N, Neubert S, Neufeld N, Newcombe R, Niel EM, Nieswand S, Nikitin N, Nolte NS, Normand C, Nunez C, Oblakowska-Mucha A, Obraztsov V, Oeser T, O'Hanlon DP, Okamura S, Oldeman R, Oliva F, Olivares ME, Onderwater CJG, O'Neil RH, Otalora Goicochea JM, Ovsiannikova T, Owen P, Oyanguren A, Ozcelik O, Padeken KO, Pagare B, Pais PR, Pajero T, Palano A, Palutan M, Pan Y, Panshin G, Papanestis A, Pappagallo M, Pappalardo LL, Pappenheimer C, Parker W, Parkes C, Passalacqua B, Passaleva G, Pastore A, Patel M, Patrignani C, Pawley CJ, Pearce A, Pellegrino A, Pepe Altarelli M, Perazzini S, Pereima D, Pereiro Castro A, Perret P, Petric M, Petridis K, Petrolini A, Petrov A, Petrucci S, Petruzzo M, Pham TTH, Philippov A, Piandani R, Pica L, Piccini M, Pietrzyk B, Pietrzyk G, Pili M, Pinci D, Pisani F, Pizzichemi M, Placinta V, Plews J, Plo Casasus M, Polci F, Poli Lener M, Poliakova M, Poluektov A, Polukhina N, Polyakov I, Polycarpo E, Ponce S, Popov D, Popov S, Poslavskii S, Prasanth K, Promberger L, Prouve C, Pugatch V, Puill V, Punzi G, Qi H, Qian W, Qin N, Qu S, Quagliani R, Raab NV, Rabadan Trejo RI, Rachwal B, Rademacker JH, Rajagopalan R, Rama M, Ramos Pernas M, Rangel MS, Ratnikov F, Raven G, Rebollo De Miguel M, Reboud M, Redi F, Reiss F, Remon Alepuz C, Ren Z, Renaudin V, Resmi PK, Ribatti R, Ricci AM, Ricciardi S, Rinnert K, Robbe P, Robertson G, Rodrigues AB, Rodrigues E, Rodriguez Lopez JA, Rodriguez Rodriguez ERR, Rollings A, Roloff P, Romanovskiy V, Romero Lamas M, Romero Vidal A, Rosello M, Roth JD, Rotondo M, Rudolph MS, Ruf T, Ruiz Fernandez RA, Ruiz Vidal J, Ryzhikov A, Ryzka J, Saborido Silva JJ, Sagidova N, Sahoo N, Saitta B, Salomoni M, Sanchez Gras C, Sanderswood I, Santacesaria R, Santamarina Rios C, Santimaria M, Santovetti E, Saranin D, Sarpis G, Sarpis M, Sarti A, Satriano C, Satta A, Saur M, Savrina D, Sazak H, Scantlebury Smead LG, Scarabotto A, Schael S, Scherl S, Schiller M, Schindler H, Schmelling M, Schmidt B, Schmitt S, Schneider O, Schopper A, Schubiger M, Schulte S, Schune MH, Schwemmer R, Sciascia B, Sciuccati A, Sellam S, Semennikov A, Senghi Soares M, Sergi A, Serra N, Sestini L, Seuthe A, Shang Y, Shangase DM, Shapkin M, Shchemerov I, Shchutska L, Shears T, Shekhtman L, Shen Z, Sheng S, Shevchenko V, Shields EB, Shimizu Y, Shmanin E, Shupperd JD, Siddi BG, Silva Coutinho R, Simi G, Simone S, Singla M, Skidmore N, Skuza R, Skwarnicki T, Slater MW, Slazyk I, Smallwood JC, Smeaton JG, Smith E, Smith M, Snoch A, Soares Lavra L, Sokoloff MD, Soler FJP, Solomin A, Solovev A, Solovyev I, Souza De Almeida FL, Souza De Paula B, Spaan B, Spadaro Norella E, Spradlin P, Sriskaran V, Stagni F, Stahl M, Stahl S, Stanislaus S, Steinkamp O, Stenyakin O, Stevens H, Stone S, Strekalina D, Suljik F, Sun J, Sun L, Sun Y, Svihra P, Swallow PN, Swientek K, Szabelski A, Szumlak T, Szymanski M, Taneja S, Tanner AR, Tat MD, Terentev A, Teubert F, Thomas E, Thompson DJD, Thomson KA, Tilquin H, Tisserand V, T'Jampens S, Tobin M, Tomassetti L, Tong X, Torres Machado D, Tou DY, Trifonova E, Trilov SM, Trippl C, Tuci G, Tully A, Tuning N, Ukleja A, Unverzagt DJ, Ursov E, Usachov A, Ustyuzhanin A, Uwer U, Vagner A, Vagnoni V, Valassi A, Valenti G, Valls Canudas N, van Beuzekom M, Van Dijk M, Van Hecke H, van Herwijnen E, van Veghel M, Vazquez Gomez R, Vazquez Regueiro P, Vázquez Sierra C, Vecchi S, Velthuis JJ, Veltri M, Venkateswaran A, Veronesi M, Vesterinen M, Vieira D, Vieites Diaz M, Viemann H, Vilasis-Cardona X, Vilella Figueras E, Villa A, Vincent P, Volle FC, Vom Bruch D, Vorobyev A, Vorobyev V, Voropaev N, Vos K, Waldi R, Walsh J, Wang C, Wang J, Wang J, Wang J, Wang J, Wang M, Wang R, Wang Y, Wang Z, Wang Z, Wang Z, Ward JA, Watson NK, Websdale D, Weisser C, Westhenry BDC, White DJ, Whitehead M, Wiederhold AR, Wiedner D, Wilkinson G, Wilkinson MK, Williams I, Williams M, Williams MRJ, Williams R, Wilson FF, Wislicki W, Witek M, Witola L, Wong CP, Wormser G, Wotton SA, Wu H, Wyllie K, Xiang Z, Xiao D, Xie Y, Xu A, Xu J, Xu L, Xu M, Xu Q, Xu Z, Xu Z, Yang D, Yang S, Yang Y, Yang Z, Yang Z, Yao Y, Yeomans LE, Yin H, Yu J, Yuan X, Yushchenko O, Zaffaroni E, Zavertyaev M, Zdybal M, Zenaiev O, Zeng M, Zhang D, Zhang L, Zhang S, Zhang S, Zhang Y, Zhang Y, Zharkova A, Zhelezov A, Zheng Y, Zhou T, Zhou X, Zhou Y, Zhovkovska V, Zhu X, Zhu X, Zhu Z, Zhukov V, Zou Q, Zucchelli S, Zuliani D, Zunica G. First Measurement of the Z→μ^{+}μ^{-} Angular Coefficients in the Forward Region of pp Collisions at sqrt[s]=13 TeV. PHYSICAL REVIEW LETTERS 2022; 129:091801. [PMID: 36083649 DOI: 10.1103/physrevlett.129.091801] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/07/2022] [Accepted: 07/13/2022] [Indexed: 06/15/2023]
Abstract
The first study of the angular distribution of μ^{+}μ^{-} pairs produced in the forward rapidity region via the Drell-Yan reaction pp→γ^{*}/Z+X→ℓ^{+}ℓ^{-}+X is presented, using data collected with the LHCb detector at a center-of-mass energy of 13 TeV, corresponding to an integrated luminosity of 5.1 fb^{-1}. The coefficients of the five leading terms in the angular distribution are determined as a function of the dimuon transverse momentum and rapidity. The results are compared to various theoretical predictions of the Z-boson production mechanism and can also be used to probe transverse-momentum-dependent parton distributions within the proton.
Collapse
|
116
|
Zhang X, Yang Z, Hu Q, Zuo L, Song X, Geng Z, Li J, Wang Y, Ge S, Hu J. [Centromere protein U is highly expressed in colorectal cancer and associated with a poor long-term prognosis]. NAN FANG YI KE DA XUE XUE BAO = JOURNAL OF SOUTHERN MEDICAL UNIVERSITY 2022; 42:1198-1204. [PMID: 36073219 DOI: 10.12122/j.issn.1673-4254.2022.08.12] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Abstract
OBJECTIVE To analyze the expression of centromere protein U (CENPU) in colorectal cancer and its predictive value for long-term prognosis of the patients. METHODS We retrospectively analyzed the data of 102 patients with colorectal cancer undergoing radical resection in our hospital between January, 2005 and December, 2011. The expression level of CENPU in colorectal cancer tissue was detected immunohistochemically, and its association with clinicopathological characteristics of the patients were analyzed. The patients were divided into low expression group (n=51) and high expression group (n=51) based on the median CENPU expression level for analysis the value of CENPU for predicting long-term prognosis of the patients after radical resection of the tumors. In the in vitro study, we constructed colorectal cancer cell lines with CENPU interference and CENPU overexpression by lentiviral transfection and assessed the changes in the proliferation, migration and invasion of the cells using CCK-8 assay and Transwell assay. RESULTS The protein expression level of CENPU was significantly higher in colorectal cancer tissues than in the adjacent tissues (P < 0.05) and was positively correlated with the expressions levels of Ki67 (r=0.569, P < 0.05) and VEGF-C (r=0.629, P < 0.05). CENPU expression level in colorectal cancer tissue was closely related with tumor progression and clinicopathological stage of the tumor (P < 0.05). Kaplan-Meier survival analysis showed that the patients with high CENPU expression had significantly decreased postoperative overall survival (χ2=11.155, P < 0.05); Cox multivariate regression analysis suggested that CENPU expression level was an independent risk factor affecting the overall survival of the patients after radical resection (HR=1.848, P < 0.05). The results of cell experiments demonstrated that high CENPU expression significantly promoted the proliferation, migration and invasion of the tumor cells. CONCLUSION CENPU is highly expressed in colorectal cancer tissues in closely correlation with tumor progression and may serve as a potential biomarker for evaluating the long-term prognosis of colorectal cancer patients.
Collapse
|
117
|
Wang C, Segal LN, Hu J, Zhou B, Hayes RB, Ahn J, Li H. Microbial risk score for capturing microbial characteristics, integrating multi-omics data, and predicting disease risk. MICROBIOME 2022; 10:121. [PMID: 35932029 PMCID: PMC9354433 DOI: 10.1186/s40168-022-01310-2] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 12/14/2021] [Accepted: 06/20/2022] [Indexed: 05/27/2023]
Abstract
BACKGROUND With the rapid accumulation of microbiome-wide association studies, a great amount of microbiome data are available to study the microbiome's role in human disease and advance the microbiome's potential use for disease prediction. However, the unique features of microbiome data hinder its utility for disease prediction. METHODS Motivated from the polygenic risk score framework, we propose a microbial risk score (MRS) framework to aggregate the complicated microbial profile into a summarized risk score that can be used to measure and predict disease susceptibility. Specifically, the MRS algorithm involves two steps: (1) identifying a sub-community consisting of the signature microbial taxa associated with disease and (2) integrating the identified microbial taxa into a continuous score. The first step is carried out using the existing sophisticated microbial association tests and pruning and thresholding method in the discovery samples. The second step constructs a community-based MRS by calculating alpha diversity on the identified sub-community in the validation samples. Moreover, we propose a multi-omics data integration method by jointly modeling the proposed MRS and other risk scores constructed from other omics data in disease prediction. RESULTS Through three comprehensive real-data analyses using the NYU Langone Health COVID-19 cohort, the gut microbiome health index (GMHI) multi-study cohort, and a large type 1 diabetes cohort separately, we exhibit and evaluate the utility of the proposed MRS framework for disease prediction and multi-omics data integration. In addition, the disease-specific MRSs for colorectal adenoma, colorectal cancer, Crohn's disease, and rheumatoid arthritis based on the relative abundances of 5, 6, 12, and 6 microbial taxa, respectively, are created and validated using the GMHI multi-study cohort. Especially, Crohn's disease MRS achieves AUCs of 0.88 (0.85-0.91) and 0.86 (0.78-0.95) in the discovery and validation cohorts, respectively. CONCLUSIONS The proposed MRS framework sheds light on the utility of the microbiome data for disease prediction and multi-omics integration and provides a great potential in understanding the microbiome's role in disease diagnosis and prognosis. Video Abstract.
Collapse
|
118
|
Tang M, Yan X, Gao J, Li L, Zhe X, Zhang X, Jiang F, Hu J, Ma N, Ai K, Zhang X. High-Resolution MRI for Evaluation of the Possibility of Successful Recanalization in Symptomatic Chronic ICA Occlusion: A Retrospective Study. AJNR Am J Neuroradiol 2022; 43:1164-1171. [PMID: 35863780 PMCID: PMC9575431 DOI: 10.3174/ajnr.a7576] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2022] [Accepted: 05/31/2022] [Indexed: 11/07/2022]
Abstract
BACKGROUND AND PURPOSE Accurate radiologic evaluation of the possibility of successful recanalization in symptomatic chronic ICA occlusion remains challenging. This study aimed to investigate the high-resolution MR imaging characteristics of symptomatic chronic ICA occlusion and their association with successful recanalization. MATERIALS AND METHODS Consecutive patients with symptomatic chronic ICA occlusion who underwent balloon dilation plus stent implantation were identified retrospectively and divided into 2 groups: a successful recanalization group and an unsuccessful recanalization group. Clinical and high-resolution MR imaging characteristics were compared between the groups. Univariate and multivariate analyses were used to identify the characteristics associated with successful recanalization. RESULTS A total of 114 patients were included in the study. High-resolution MR imaging characteristics independently associated with unsuccessful recanalization were longer lesion length (OR, 0.41; 95% CI, 0.36-0.55; P = .009) and larger calcification volume (OR, 0.56; 95% CI, 0.37-0.68; P = .002) for proximal occlusion and reversed distal ICA flow at the level of ophthalmic segment or above (OR, 0.14; 95% CI, 0.08-0.48; P = .001). Reversed distal ICA flow at the level of the petrous segment or below (OR, 4.07; 95% CI, 1.65-8.38; P = .001) and lumen area (OR, 1.13; 95% CI, 1.04-1.61; P = .002) for distal occlusion were risk factors of successful recanalization. CONCLUSIONS In symptomatic chronic ICA occlusion, lesion length and calcification volume (for proximal occlusion), the level of reversed distal ICA flow, and the lumen area (for distal occlusion) appear to be predictors of successful recanalization. High-resolution MR imaging can evaluate chronic ICA occlusion and help in clinical decision-making.
Collapse
|
119
|
Aaij R, Abdelmotteleb ASW, Beteta CA, Gallego FJA, Ackernley T, Adeva B, Adinolfi M, Afsharnia H, Agapopoulou C, Aidala CA, Aiola S, Ajaltouni Z, Akar S, Albrecht J, Alessio F, Alexander M, Albero AA, Aliouche Z, Alkhazov G, Cartelle PA, Amato S, Amey JL, Amhis Y, An L, Anderlini L, Andreianov A, Andreotti M, Archilli F, Artamonov A, Artuso M, Arzymatov K, Aslanides E, Atzeni M, Audurier B, Bachmann S, Bachmayer M, Back JJ, Rodriguez PB, Balagura V, Baldini W, Leite JB, Barbetti M, Barlow RJ, Barsuk S, Barter W, Bartolini M, Baryshnikov F, Basels JM, Bashir S, Bassi G, Batsukh B, Battig A, Bay A, Beck A, Becker M, Bedeschi F, Bediaga I, Beiter A, Belavin V, Belin S, Bellee V, Belous K, Belov I, Belyaev I, Bencivenni G, Ben-Haim E, Berezhnoy A, Bernet R, Berninghoff D, Bernstein HC, Bertella C, Bertolin A, Betancourt C, Betti F, Bezshyiko I, Bhasin S, Bhom J, Bian L, Bieker MS, Bifani S, Billoir P, Birch M, Bishop FCR, Bitadze A, Bizzeti A, Bjørn M, Blago MP, Blake T, Blanc F, Blusk S, Bobulska D, Boelhauve JA, Garcia OB, Boettcher T, Boldyrev A, Bondar A, Bondar N, Borghi S, Borisyak M, Borsato M, Borsuk JT, Bouchiba SA, Bowcock TJV, Boyer A, Bozzi C, Bradley MJ, Braun S, Rodriguez AB, Brodzicka J, Gonzalo AB, Brundu D, Buonaura A, Buonincontri L, Burke AT, Burr C, Bursche A, Butkevich A, Butter JS, Buytaert J, Byczynski W, Cadeddu S, Cai H, Calabrese R, Calefice L, Diaz LC, Cali S, Calladine R, Calvi M, Gomez MC, Magalhaes PC, Campana P, Quezada AFC, Capelli S, Capriotti L, Carbone A, Carboni G, Cardinale R, Cardini A, Carli I, Carniti P, Carus L, Akiba KC, Vidal AC, Casse G, Cattaneo M, Cavallero G, Celani S, Cerasoli J, Cervenkov D, Chadwick AJ, Chapman MG, Charles M, Charpentier P, Chatzikonstantinidis G, Barajas CAC, Chefdeville M, Chen C, Chen S, Chernov A, Chobanova V, Cholak S, Chrzaszcz M, Chubykin A, Chulikov V, Ciambrone P, Cicala MF, Vidal XC, Ciezarek G, Clarke PEL, Clemencic M, Cliff HV, Closier J, Cobbledick JL, Coco V, Coelho JAB, Cogan J, Cogneras E, Cojocariu L, Collins P, Colombo T, Congedo L, Contu A, Cooke N, Coombs G, Corredoira I, Corti G, Sobral CMC, Couturier B, Craik DC, Crkovská J, Torres MC, Currie R, Silva CLD, Dadabaev S, Dai L, Dall’Occo E, Dalseno J, D’Ambrosio C, Danilina A, d’Argent P, Davies JE, Davis A, De Aguiar Francisco O, De Bruyn K, De Capua S, De Cian M, De Miranda JM, De Paula L, De Serio M, De Simone D, De Simone P, De Vellis F, de Vries JA, Dean CT, Debernardis F, Decamp D, Dedu V, Buono LD, Delaney B, Dembinski HP, Dendek A, Denysenko V, Derkach D, Deschamps O, Desse F, Dettori F, Dey B, Cicco AD, Nezza PD, Didenko S, Maronas LD, Dijkstra H, Dobishuk V, Dong C, Donohoe AM, Dordei F, dos Reis AC, Douglas L, Dovbnya A, Downes AG, Dudek MW, Dufour L, Duk V, Durante P, Durham JM, Dutta D, Dziurda A, Dzyuba A, Easo S, Egede U, Egorychev V, Eidelman S, Eisenhardt S, Ek-In S, Eklund L, Ely S, Ene A, Epple E, Escher S, Eschle J, Esen S, Evans T, Falabella A, Fan J, Fan Y, Fang B, Farry S, Fazzini D, Féo M, Prieto AF, Fernez AD, Ferrari F, Lopes LF, Rodrigues FF, Sole SF, Ferrillo M, Ferro-Luzzi M, Filippov S, Fini RA, Fiorini M, Firlej M, Fischer KM, Fitzgerald DS, Fitzpatrick C, Fiutowski T, Fkiaras A, Fleuret F, Fontana M, Fontanelli F, Forty R, Foulds-Holt D, Lima VF, Sevilla MF, Frank M, Franzoso E, Frau G, Frei C, Friday DA, Fu J, Fuehring Q, Gabriel E, Galati G, Torreira AG, Galli D, Gambetta S, Gan Y, Gandelman M, Gandini P, Gao Y, Garau M, Martin LMG, Moreno PG, Pardiñas JG, Plana BG, Rosales FAG, Garrido L, Gaspar C, Geertsema RE, Gerick D, Gerken LL, Gersabeck E, Gersabeck M, Gershon T, Gerstel D, Giambastiani L, Gibson V, Giemza HK, Gilman AL, Giovannetti M, Gioventù A, Gironell PG, Giubega L, Giugliano C, Gizdov K, Gkougkousis EL, Gligorov VV, Göbel C, Golobardes E, Golubkov D, Golutvin A, Gomes A, Fernandez SG, Abrantes FG, Goncerz M, Gong G, Gorbounov P, Gorelov IV, Gotti C, Govorkova E, Grabowski JP, Grammatico T, Cardoso LAG, Graugés E, Graverini E, Graziani G, Grecu A, Greeven LM, Grieser NA, Grillo L, Gromov S, Cazon BRG, Gu C, Guarise M, Guittiere M, Günther PA, Gushchin E, Guth A, Guz Y, Gys T, Hadavizadeh T, Haefeli G, Haen C, Haimberger J, Halewood-leagas T, Hamilton PM, Hammerich JP, Han Q, Han X, Hancock TH, Hansen EB, Hansmann-Menzemer S, Harnew N, Harrison T, Hasse C, Hatch M, He J, Hecker M, Heijhoff K, Heinicke K, Hennequin AM, Hennessy K, Henry L, Heuel J, Hicheur A, Hill D, Hilton M, Hollitt SE, Hou R, Hou Y, Hu J, Hu J, Hu W, Hu X, Huang W, Huang X, Hulsbergen W, Hunter RJ, Hushchyn M, Hutchcroft D, Hynds D, Ibis P, Idzik M, Ilin D, Ilten P, Inglessi A, Ishteev A, Ivshin K, Jacobsson R, Jage H, Jakobsen S, Jans E, Jashal BK, Jawahery A, Jevtic V, Jiang F, John M, Johnson D, Jones CR, Jones TP, Jost B, Jurik N, Kadavath SHK, Kandybei S, Kang Y, Karacson M, Karpov M, Keizer F, Keller DM, Kenzie M, Ketel T, Khanji B, Kharisova A, Kholodenko S, Kirn T, Kirsebom VS, Kitouni O, Klaver S, Kleijne N, Klimaszewski K, Kmiec MR, Koliiev S, Kondybayeva A, Konoplyannikov A, Kopciewicz P, Kopecna R, Koppenburg P, Korolev M, Kostiuk I, Kot O, Kotriakhova S, Kravchenko P, Kravchuk L, Krawczyk RD, Kreps M, Kress F, Kretzschmar S, Krokovny P, Krupa W, Krzemien W, Kucharczyk M, Kudryavtsev V, Kuindersma HS, Kunde GJ, Kvaratskheliya T, Lacarrere D, Lafferty G, Lai A, Lampis A, Lancierini D, Lane JJ, Lane R, Lanfranchi G, Langenbruch C, Langer J, Lantwin O, Latham T, Lazzari F, Gac RL, Lee SH, Lefèvre R, Leflat A, Legotin S, Leroy O, Lesiak T, Leverington B, Li H, Li P, Li S, Li Y, Li Z, Liang X, Lin T, Lindner R, Lisovskyi V, Litvinov R, Liu G, Liu H, Liu Q, Liu S, Salvia AL, Loi A, Castro JL, Longstaff I, Lopes JH, Solino SL, Lovell GH, Lu Y, Lucarelli C, Lucchesi D, Luchuk S, Martinez ML, Lukashenko V, Luo Y, Lupato A, Luppi E, Lupton O, Lusiani A, Lyu X, Ma L, Ma R, Maccolini S, Machefert F, Maciuc F, Macko V, Mackowiak P, Maddrell-Mander S, Madejczyk O, Mohan LRM, Maev O, Maevskiy A, Maisuzenko D, Majewski MW, Malczewski JJ, Malde S, Malecki B, Malinin A, Maltsev T, Malygina H, Manca G, Mancinelli G, Manuzzi D, Marangotto D, Maratas J, Marchand JF, Marconi U, Mariani S, Benito CM, Marinangeli M, Marks J, Marshall AM, Marshall PJ, Martelli G, Martellotti G, Martinazzoli L, Martinelli M, Santos DM, Vidal FM, Massafferri A, Materok M, Matev R, Mathad A, Matiunin V, Matteuzzi C, Mattioli KR, Mauri A, Maurice E, Mauricio J, Mazurek M, McCann M, Mcconnell L, Mcgrath TH, Mchugh NT, McNab A, McNulty R, Mead JV, Meadows B, Meier G, Meinert N, Melnychuk D, Meloni S, Merk M, Merli A, Garcia LM, Mikhasenko M, Milanes DA, Millard E, Milovanovic M, Minard MN, Minotti A, Minzoni L, Mitchell SE, Mitreska B, Mitzel DS, Mödden A, Mohammed RA, Moise RD, Mokhnenko S, Mombächer T, Monroy IA, Monteil S, Morandin M, Morello G, Morello MJ, Moron J, Morris AB, Morris AG, Mountain R, Mu H, Muheim F, Mulder M, Müller D, Müller K, Murphy CH, Murray D, Muzzetto P, Naik P, Nakada T, Nandakumar R, Nanut T, Nasteva I, Needham M, Neri I, Neri N, Neubert S, Neufeld N, Newcombe R, Niel EM, Nieswand S, Nikitin N, Nolte NS, Normand C, Nunez C, Oblakowska-Mucha A, Obraztsov V, Oeser T, O’Hanlon DP, Okamura S, Oldeman R, Oliva F, Olivares ME, Onderwater CJG, O’neil RH, Goicochea JMO, Ovsiannikova T, Owen P, Oyanguren A, Padeken KO, Pagare B, Pais PR, Pajero T, Palano A, Palutan M, Pan Y, Panshin G, Papanestis A, Pappagallo M, Pappalardo LL, Pappenheimer C, Parker W, Parkes C, Passalacqua B, Passaleva G, Pastore A, Patel M, Patrignani C, Pawley CJ, Pearce A, Pellegrino A, Altarelli MP, Perazzini S, Pereima D, Castro AP, Perret P, Petric M, Petridis K, Petrolini A, Petrov A, Petrucci S, Petruzzo M, Pham TTH, Pica L, Piccini M, Pietrzyk B, Pietrzyk G, Pili M, Pinci D, Pisani F, Pizzichemi M, Resmi PK, Placinta V, Plews J, Casasus MP, Polci F, Lener MP, Poliakova M, Poluektov A, Polukhina N, Polyakov I, Polycarpo E, Ponce S, Popov D, Popov S, Poslavskii S, Prasanth K, Promberger L, Prouve C, Pugatch V, Puill V, Pullen H, Punzi G, Qi H, Qian W, Qin J, Qin N, Quagliani R, Quintana B, Raab NV, Trejo RIR, Rachwal B, Rademacker JH, Rama M, Pernas MR, Rangel MS, Ratnikov F, Raven G, Reboud M, Redi F, Reiss F, Alepuz CR, Ren Z, Renaudin V, Ribatti R, Ricciardi S, Rinnert K, Robbe P, Robertson G, Rodrigues AB, Rodrigues E, Lopez JAR, Rodriguez ERRR, Rollings A, Roloff P, Romanovskiy V, Lamas MR, Vidal AR, Roth JD, Rotondo M, Rudolph MS, Ruf T, Fernandez RAR, Vidal JR, Ryzhikov A, Ryzka J, Silva JJS, Sagidova N, Sahoo N, Saitta B, Salomoni M, Gras CS, Santacesaria R, Rios CS, Santimaria M, Santovetti E, Saranin D, Sarpis G, Sarpis M, Sarti A, Satriano C, Satta A, Saur M, Savrina D, Sazak H, Smead LGS, Scarabotto A, Schael S, Scherl S, Schiller M, Schindler H, Schmelling M, Schmidt B, Schmitt S, Schneider O, Schopper A, Schubiger M, Schulte S, Schune MH, Schwemmer R, Sciascia B, Sellam S, Semennikov A, Soares MS, Sergi A, Serra N, Sestini L, Seuthe A, Shang Y, Shangase DM, Shapkin M, Shchemerov I, Shchutska L, Shears T, Shekhtman L, Shen Z, Shevchenko V, Shields EB, Shimizu Y, Shmanin E, Shupperd JD, Siddi BG, Coutinho RS, Simi G, Simone S, Skidmore N, Skwarnicki T, Slater MW, Slazyk I, Smallwood JC, Smeaton JG, Smetkina A, Smith E, Smith M, Snoch A, Soares M, Lavra LS, Sokoloff MD, Soler FJP, Solovev A, Solovyev I, De Almeida FLS, De Paula BS, Spaan B, Norella ES, Spradlin P, Stagni F, Stahl M, Stahl S, Stanislaus S, Steinkamp O, Stenyakin O, Stevens H, Stone S, Straticiuc M, Strekalina D, Suljik F, Sun J, Sun L, Sun Y, Svihra P, Swallow PN, Swientek K, Szabelski A, Szumlak T, Szymanski M, Taneja S, Tanner AR, Tat MD, Terentev A, Teubert F, Thomas E, Thompson DJD, Thomson KA, Tisserand V, T’Jampens S, Tobin M, Tomassetti L, Tong X, Machado DT, Tou DY, Trifonova E, Trippl C, Tuci G, Tully A, Tuning N, Ukleja A, Unverzagt DJ, Ursov E, Usachov A, Ustyuzhanin A, Uwer U, Vagner A, Vagnoni V, Valassi A, Valenti G, Canudas NV, van Beuzekom M, Dijk MV, van Herwijnen E, Van Hulse CB, van Veghel M, Gomez RV, Regueiro PV, Sierra CV, Vecchi S, Velthuis JJ, Veltri M, Venkateswaran A, Veronesi M, Vesterinen M, Vieira D, Diaz MV, Viemann H, Vilasis-Cardona X, Figueras EV, Villa A, Vincent P, Volle FC, Bruch DV, Vorobyev A, Vorobyev V, Voropaev N, Vos K, Waldi R, Walsh J, Wang C, Wang J, Wang J, Wang J, Wang J, Wang M, Wang R, Wang Y, Wang Z, Wang Z, Wang Z, Ward JA, Watson NK, Weber SG, Websdale D, Weisser C, Westhenry BDC, White DJ, Whitehead M, Wiederhold AR, Wiedner D, Wilkinson G, Wilkinson M, Williams I, Williams M, Williams MRJ, Wilson FF, Wislicki W, Witek M, Witola L, Wormser G, Wotton SA, Wu H, Wyllie K, Xiang Z, Xiao D, Xie Y, Xu A, Xu J, Xu L, Xu M, Xu Q, Xu Z, Xu Z, Yang D, Yang S, Yang Y, Yang Z, Yang Z, Yao Y, Yeomans LE, Yin H, Yu J, Yuan X, Yushchenko O, Zaffaroni E, Zavertyaev M, Zdybal M, Zenaiev O, Zeng M, Zhang D, Zhang L, Zhang S, Zhang S, Zhang Y, Zhang Y, Zharkova A, Zhelezov A, Zheng Y, Zhou T, Zhou X, Zhou Y, Zhovkovska V, Zhu X, Zhu X, Zhu Z, Zhukov V, Zonneveld JB, Zou Q, Zucchelli S, Zuliani D, Zunica G. Study of the doubly charmed tetraquark [Formula: see text]. Nat Commun 2022; 13:3351. [PMID: 35710739 PMCID: PMC9203551 DOI: 10.1038/s41467-022-30206-w] [Citation(s) in RCA: 18] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/07/2021] [Accepted: 04/14/2022] [Indexed: 11/24/2022] Open
Abstract
Quantum chromodynamics, the theory of the strong force, describes interactions of coloured quarks and gluons and the formation of hadronic matter. Conventional hadronic matter consists of baryons and mesons made of three quarks and quark-antiquark pairs, respectively. Particles with an alternative quark content are known as exotic states. Here a study is reported of an exotic narrow state in the D0D0π+ mass spectrum just below the D*+D0 mass threshold produced in proton-proton collisions collected with the LHCb detector at the Large Hadron Collider. The state is consistent with the ground isoscalar [Formula: see text] tetraquark with a quark content of [Formula: see text] and spin-parity quantum numbers JP = 1+. Study of the DD mass spectra disfavours interpretation of the resonance as the isovector state. The decay structure via intermediate off-shell D*+ mesons is consistent with the observed D0π+ mass distribution. To analyse the mass of the resonance and its coupling to the D*D system, a dedicated model is developed under the assumption of an isoscalar axial-vector [Formula: see text] state decaying to the D*D channel. Using this model, resonance parameters including the pole position, scattering length, effective range and compositeness are determined to reveal important information about the nature of the [Formula: see text] state. In addition, an unexpected dependence of the production rate on track multiplicity is observed.
Collapse
|
120
|
Wang C, Segal LN, Hu J, Zhou B, Hayes R, Ahn J, Li H. Microbial Risk Score for Capturing Microbial Characteristics, Integrating Multi-omics Data, and Predicting Disease Risk. BIORXIV : THE PREPRINT SERVER FOR BIOLOGY 2022. [PMID: 35702150 PMCID: PMC9196107 DOI: 10.1101/2022.06.07.495127] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
Background: With the rapid accumulation of microbiome-wide association studies, a great amount of microbiome data are available to study the microbiome’s role in human disease and advance the microbiome’s potential use for disease prediction. However, the unique features of microbiome data hinder its utility for disease prediction. Methods: Motivated from the polygenic risk score framework, we propose a microbial risk score (MRS) framework to aggregate the complicated microbial profile into a summarized risk score that can be used to measure and predict disease susceptibility. Specifically, the MRS algorithm involves two steps: 1) identifying a sub-community consisting of the signature microbial taxa associated with disease, and 2) integrating the identified microbial taxa into a continuous score. The first step is carried out using the existing sophisticated microbial association tests and pruning and thresholding method in the discovery samples. The second step constructs a community-based MRS by calculating alpha diversity on the identified sub-community in the validation samples. Moreover, we propose a multi-omics data integration method by jointly modeling the proposed MRS and other risk scores constructed from other omics data in disease prediction. Results: Through three comprehensive real data analyses using the NYU Langone Health COVID-19 cohort, the gut microbiome health index (GMHI) multi-study cohort, and a large type 1 diabetes cohort separately, we exhibit and evaluate the utility of the proposed MRS framework for disease prediction and multi-omics data integration. In addition, the disease-specific MRSs for colorectal adenoma, colorectal cancer, Crohn’s disease, and rheumatoid arthritis based on the relative abundances of 5, 6, 12, and 6 microbial taxa respectively are created and validated using the GMHI multi-study cohort. Especially, Crohn’s disease MRS achieves AUCs of 0.88 ([0.85–0.91]) and 0.86 ([0.78–0.95]) in the discovery and validation cohorts, respectively. Conclusions: The proposed MRS framework sheds light on the utility of the microbiome data for disease prediction and multi-omics integration, and provides great potential in understanding the microbiome’s role in disease diagnosis and prognosis.
Collapse
|
121
|
Aaij R, Abdelmotteleb ASW, Abellán Beteta C, Abudinén F, Ackernley T, Adeva B, Adinolfi M, Afsharnia H, Agapopoulou C, Aidala CA, Aiola S, Ajaltouni Z, Akar S, Albrecht J, Alessio F, Alexander M, Alfonso Albero A, Aliouche Z, Alkhazov G, Alvarez Cartelle P, Alves AA, Amato S, Amey JL, Amhis Y, An L, Anderlini L, Andersson N, Andreianov A, Andreotti M, Archilli F, Artamonov A, Artuso M, Arzymatov K, Aslanides E, Atzeni M, Audurier B, Bachmann S, Bachmayer M, Back JJ, Baladron Rodriguez P, Balagura V, Baldini W, Baptista Leite J, Barbetti M, Barlow RJ, Barsuk S, Barter W, Bartolini M, Baryshnikov F, Basels JM, Bashir S, Bassi G, Batsukh B, Battig A, Bay A, Beck A, Becker M, Bedeschi F, Bediaga I, Beiter A, Belavin V, Belin S, Bellee V, Belous K, Belov I, Belyaev I, Bencivenni G, Ben-Haim E, Berezhnoy A, Bernet R, Berninghoff D, Bernstein HC, Bertella C, Bertolin A, Betancourt C, Betti F, Bezshyiko I, Bhasin S, Bhom J, Bian L, Bieker MS, Biesuz NV, Bifani S, Billoir P, Biolchini A, Birch M, Bishop FCR, Bitadze A, Bizzeti A, Bjørn M, Blago MP, Blake T, Blanc F, Blusk S, Bobulska D, Boelhauve JA, Boente Garcia O, Boettcher T, Boldyrev A, Bondar A, Bondar N, Borghi S, Borisyak M, Borsato M, Borsuk JT, Bouchiba SA, Bowcock TJV, Boyer A, Bozzi C, Bradley MJ, Braun S, Brea Rodriguez A, Brodzicka J, Brossa Gonzalo A, Brundu D, Buonaura A, Buonincontri L, Burke AT, Burr C, Bursche A, Butkevich A, Butter JS, Buytaert J, Byczynski W, Cadeddu S, Cai H, Calabrese R, Calefice L, Cali S, Calladine R, Calvi M, Calvo Gomez M, Camargo Magalhaes P, Campana P, Campoverde Quezada AF, Capelli S, Capriotti L, Carbone A, Carboni G, Cardinale R, Cardini A, Carli I, Carniti P, Carus L, Carvalho Akiba K, Casais Vidal A, Caspary R, Casse G, Cattaneo M, Cavallero G, Celani S, Cerasoli J, Cervenkov D, Chadwick AJ, Chapman MG, Charles M, Charpentier P, Chatzikonstantinidis G, Chavez Barajas CA, Chefdeville M, Chen C, Chen S, Chernov A, Chobanova V, Cholak S, Chrzaszcz M, Chubykin A, Chulikov V, Ciambrone P, Cicala MF, Cid Vidal X, Ciezarek G, Clarke PEL, Clemencic M, Cliff HV, Closier J, Cobbledick JL, Coco V, Coelho JAB, Cogan J, Cogneras E, Cojocariu L, Collins P, Colombo T, Congedo L, Contu A, Cooke N, Coombs G, Corredoira I, Corti G, Costa Sobral CM, Couturier B, Craik DC, Crkovská J, Cruz Torres M, Currie R, Da Silva CL, Dadabaev S, Dai L, Dall'Occo E, Dalseno J, D'Ambrosio C, Danilina A, d'Argent P, Dashkina A, Davies JE, Davis A, De Aguiar Francisco O, De Bruyn K, De Capua S, De Cian M, De Lucia E, De Miranda JM, De Paula L, De Serio M, De Simone D, De Simone P, De Vellis F, de Vries JA, Dean CT, Debernardis F, Decamp D, Dedu V, Del Buono L, Delaney B, Dembinski HP, Dendek A, Denysenko V, Derkach D, Deschamps O, Desse F, Dettori F, Dey B, Di Canto A, Di Cicco A, Di Nezza P, Didenko S, Dieste Maronas L, Dijkstra H, Dobishuk V, Dong C, Donohoe AM, Dordei F, Dos Reis AC, Douglas L, Dovbnya A, Downes AG, Dudek MW, Dufour L, Duk V, Durante P, Durham JM, Dutta D, Dziurda A, Dzyuba A, Easo S, Egede U, Egorychev V, Eidelman S, Eisenhardt S, Ek-In S, Eklund L, Ely S, Ene A, Epple E, Escher S, Eschle J, Esen S, Evans T, Falcao LN, Fan Y, Fang B, Farry S, Fazzini D, Féo M, Fernandez Prieto A, Fernez AD, Ferrari F, Ferreira Lopes L, Ferreira Rodrigues F, Ferreres Sole S, Ferrillo M, Ferro-Luzzi M, Filippov S, Fini RA, Fiorini M, Firlej M, Fischer KM, Fitzgerald DS, Fitzpatrick C, Fiutowski T, Fkiaras A, Fleuret F, Fontana M, Fontanelli F, Forty R, Foulds-Holt D, Franco Lima V, Franco Sevilla M, Frank M, Franzoso E, Frau G, Frei C, Friday DA, Fu J, Fuehring Q, Gabriel E, Galati G, Gallas Torreira A, Galli D, Gambetta S, Gan Y, Gandelman M, Gandini P, Gao Y, Garau M, Garcia Martin LM, Garcia Moreno P, García Pardiñas J, Garcia Plana B, Garcia Rosales FA, Garrido L, Gaspar C, Geertsema RE, Gerick D, Gerken LL, Gersabeck E, Gersabeck M, Gershon T, Gerstel D, Giambastiani L, Gibson V, Giemza HK, Gilman AL, Giovannetti M, Gioventù A, Gironella Gironell P, Giugliano C, Gizdov K, Gkougkousis EL, Gligorov VV, Göbel C, Golobardes E, Golubkov D, Golutvin A, Gomes A, Gomez Fernandez S, Goncalves Abrantes F, Goncerz M, Gong G, Gorbounov P, Gorelov IV, Gotti C, Govorkova E, Grabowski JP, Grammatico T, Granado Cardoso LA, Graugés E, Graverini E, Graziani G, Grecu A, Greeven LM, Grieser NA, Grillo L, Gromov S, Gruberg Cazon BR, Gu C, Guarise M, Guittiere M, Günther PA, Gushchin E, Guth A, Guz Y, Gys T, Hadavizadeh T, Haefeli G, Haen C, Haimberger J, Halewood-Leagas T, Hamilton PM, Hammerich JP, Han Q, Han X, Hancock TH, Hansen EB, Hansmann-Menzemer S, Harnew N, Harrison T, Hasse C, Hatch M, He J, Hecker M, Heijhoff K, Heinicke K, Henderson RDL, Hennequin AM, Hennessy K, Henry L, Heuel J, Hicheur A, Hill D, Hilton M, Hollitt SE, Hou R, Hou Y, Hu J, Hu J, Hu W, Hu X, Huang W, Huang X, Hulsbergen W, Hunter RJ, Hushchyn M, Hutchcroft D, Hynds D, Ibis P, Idzik M, Ilin D, Ilten P, Inglessi A, Ishteev A, Ivshin K, Jacobsson R, Jage H, Jakobsen S, Jans E, Jashal BK, Jawahery A, Jevtic V, Jiang X, John M, Johnson D, Jones CR, Jones TP, Jost B, Jurik N, Kalavan Kadavath SH, Kandybei S, Kang Y, Karacson M, Karpov M, Kautz JW, Keizer F, Keller DM, Kenzie M, Ketel T, Khanji B, Kharisova A, Kholodenko S, Kirn T, Kirsebom VS, Kitouni O, Klaver S, Kleijne N, Klimaszewski K, Kmiec MR, Koliiev S, Kondybayeva A, Konoplyannikov A, Kopciewicz P, Kopecna R, Koppenburg P, Korolev M, Kostiuk I, Kot O, Kotriakhova S, Kravchenko P, Kravchuk L, Krawczyk RD, Kreps M, Kress F, Kretzschmar S, Krokovny P, Krupa W, Krzemien W, Kubat J, Kucharczyk M, Kudryavtsev V, Kuindersma HS, Kunde GJ, Kvaratskheliya T, Lacarrere D, Lafferty G, Lai A, Lampis A, Lancierini D, Lane JJ, Lane R, Lanfranchi G, Langenbruch C, Langer J, Lantwin O, Latham T, Lazzari F, Le Gac R, Lee SH, Lefèvre R, Leflat A, Legotin S, Leroy O, Lesiak T, Leverington B, Li H, Li P, Li S, Li Y, Li Y, Li Z, Liang X, Lin T, Lindner R, Lisovskyi V, Litvinov R, Liu G, Liu H, Liu Q, Liu S, Lobo Salvia A, Loi A, Lomba Castro J, Longstaff I, Lopes JH, López Soliño S, Lovell GH, Lu Y, Lucarelli C, Lucchesi D, Luchuk S, Lucio Martinez M, Lukashenko V, Luo Y, Lupato A, Luppi E, Lupton O, Lusiani A, Lyu X, Ma L, Ma R, Maccolini S, Machefert F, Maciuc F, Macko V, Mackowiak P, Maddrell-Mander S, Madejczyk O, Madhan Mohan LR, Maev O, Maevskiy A, Maisuzenko D, Majewski MW, Malczewski JJ, Malde S, Malecki B, Malinin A, Maltsev T, Malygina H, Manca G, Mancinelli G, Manuzzi D, Marangotto D, Maratas J, Marchand JF, Marconi U, Mariani S, Marin Benito C, Marinangeli M, Marks J, Marshall AM, Marshall PJ, Martelli G, Martellotti G, Martinazzoli L, Martinelli M, Martinez Santos D, Martinez Vidal F, Massafferri A, Materok M, Matev R, Mathad A, Matiunin V, Matteuzzi C, Mattioli KR, Mauri A, Maurice E, Mauricio J, Mazurek M, McCann M, Mcconnell L, Mcgrath TH, Mchugh NT, McNab A, McNulty R, Mead JV, Meadows B, Meier G, Meinert N, Melnychuk D, Meloni S, Merk M, Merli A, Meyer Garcia L, Mikhasenko M, Milanes DA, Millard E, Milovanovic M, Minard MN, Minotti A, Minzoni L, Mitchell SE, Mitreska B, Mitzel DS, Mödden A, Mohammed RA, Moise RD, Mokhnenko S, Mombächer T, Monroy IA, Monteil S, Morandin M, Morello G, Morello MJ, Moron J, Morris AB, Morris AG, Mountain R, Mu H, Muheim F, Mulder M, Müller D, Müller K, Murphy CH, Murray D, Murta R, Muzzetto P, Naik P, Nakada T, Nandakumar R, Nanut T, Nasteva I, Needham M, Neri N, Neubert S, Neufeld N, Newcombe R, Niel EM, Nieswand S, Nikitin N, Nolte NS, Normand C, Nunez C, Oblakowska-Mucha A, Obraztsov V, Oeser T, O'Hanlon DP, Okamura S, Oldeman R, Oliva F, Olivares ME, Onderwater CJG, O'Neil RH, Otalora Goicochea JM, Ovsiannikova T, Owen P, Oyanguren A, Padeken KO, Pagare B, Pais PR, Pajero T, Palano A, Palutan M, Pan Y, Panshin G, Papanestis A, Pappagallo M, Pappalardo LL, Pappenheimer C, Parker W, Parkes C, Passalacqua B, Passaleva G, Pastore A, Patel M, Patrignani C, Pawley CJ, Pearce A, Pellegrino A, Pepe Altarelli M, Perazzini S, Pereima D, Pereiro Castro A, Perret P, Petric M, Petridis K, Petrolini A, Petrov A, Petrucci S, Petruzzo M, Pham TTH, Philippov A, Piandani R, Pica L, Piccini M, Pietrzyk B, Pietrzyk G, Pili M, Pinci D, Pisani F, Pizzichemi M, P K R, Placinta V, Plews J, Plo Casasus M, Polci F, Poli Lener M, Poliakova M, Poluektov A, Polukhina N, Polyakov I, Polycarpo E, Ponce S, Popov D, Popov S, Poslavskii S, Prasanth K, Promberger L, Prouve C, Pugatch V, Puill V, Pullen H, Punzi G, Qi H, Qian W, Qin J, Qin N, Quagliani R, Quintana B, Raab NV, Rabadan Trejo RI, Rachwal B, Rademacker JH, Rama M, Ramos Pernas M, Rangel MS, Ratnikov F, Raven G, Reboud M, Redi F, Reiss F, Remon Alepuz C, Ren Z, Renaudin V, Ribatti R, Ricciardi S, Rinnert K, Robbe P, Robertson G, Rodrigues AB, Rodrigues E, Rodriguez Lopez JA, Rodriguez Rodriguez ERR, Rollings A, Roloff P, Romanovskiy V, Romero Lamas M, Romero Vidal A, Roth JD, Rotondo M, Rudolph MS, Ruf T, Ruiz Fernandez RA, Ruiz Vidal J, Ryzhikov A, Ryzka J, Saborido Silva JJ, Sagidova N, Sahoo N, Saitta B, Salomoni M, Sanchez Gras C, Santacesaria R, Santamarina Rios C, Santimaria M, Santovetti E, Saranin D, Sarpis G, Sarpis M, Sarti A, Satriano C, Satta A, Saur M, Savrina D, Sazak H, Scantlebury Smead LG, Scarabotto A, Schael S, Scherl S, Schiller M, Schindler H, Schmelling M, Schmidt B, Schmitt S, Schneider O, Schopper A, Schubiger M, Schulte S, Schune MH, Schwemmer R, Sciascia B, Sellam S, Semennikov A, Senghi Soares M, Sergi A, Serra N, Sestini L, Seuthe A, Shang Y, Shangase DM, Shapkin M, Shchemerov I, Shchutska L, Shears T, Shekhtman L, Shen Z, Sheng S, Shevchenko V, Shields EB, Shimizu Y, Shmanin E, Shupperd JD, Siddi BG, Silva Coutinho R, Simi G, Simone S, Skidmore N, Skwarnicki T, Slater MW, Slazyk I, Smallwood JC, Smeaton JG, Smetkina A, Smith E, Smith M, Snoch A, Soares Lavra L, Sokoloff MD, Soler FJP, Solovev A, Solovyev I, Souza De Almeida FL, Souza De Paula B, Spaan B, Spadaro Norella E, Spradlin P, Stagni F, Stahl M, Stahl S, Stanislaus S, Steinkamp O, Stenyakin O, Stevens H, Stone S, Strekalina D, Suljik F, Sun J, Sun L, Sun Y, Svihra P, Swallow PN, Swientek K, Szabelski A, Szumlak T, Szymanski M, Taneja S, Tanner AR, Tat MD, Terentev A, Teubert F, Thomas E, Thompson DJD, Thomson KA, Tilquin H, Tisserand V, T'Jampens S, Tobin M, Tomassetti L, Tong X, Torres Machado D, Tou DY, Trifonova E, Trilov SM, Trippl C, Tuci G, Tully A, Tuning N, Ukleja A, Unverzagt DJ, Ursov E, Usachov A, Ustyuzhanin A, Uwer U, Vagner A, Vagnoni V, Valassi A, Valenti G, Valls Canudas N, van Beuzekom M, Van Dijk M, Van Hecke H, van Herwijnen E, van Veghel M, Vazquez Gomez R, Vazquez Regueiro P, Vázquez Sierra C, Vecchi S, Velthuis JJ, Veltri M, Venkateswaran A, Veronesi M, Vesterinen M, Vieira D, Vieites Diaz M, Viemann H, Vilasis-Cardona X, Vilella Figueras E, Villa A, Vincent P, Volle FC, Vom Bruch D, Vorobyev A, Vorobyev V, Voropaev N, Vos K, Waldi R, Walsh J, Wang C, Wang J, Wang J, Wang J, Wang J, Wang M, Wang R, Wang Y, Wang Z, Wang Z, Wang Z, Ward JA, Watson NK, Weber SG, Websdale D, Weisser C, Westhenry BDC, White DJ, Whitehead M, Wiederhold AR, Wiedner D, Wilkinson G, Wilkinson M, Williams I, Williams M, Williams MRJ, Wilson FF, Wislicki W, Witek M, Witola L, Wormser G, Wotton SA, Wu H, Wyllie K, Xiang Z, Xiao D, Xie Y, Xu A, Xu J, Xu L, Xu M, Xu Q, Xu Z, Xu Z, Yang D, Yang S, Yang Y, Yang Z, Yang Z, Yao Y, Yeomans LE, Yin H, Yu J, Yuan X, Yushchenko O, Zaffaroni E, Zavertyaev M, Zdybal M, Zenaiev O, Zeng M, Zhang D, Zhang L, Zhang S, Zhang S, Zhang Y, Zhang Y, Zharkova A, Zhelezov A, Zheng Y, Zhou T, Zhou X, Zhou Y, Zhovkovska V, Zhu X, Zhu X, Zhu Z, Zhukov V, Zonneveld JB, Zou Q, Zucchelli S, Zuliani D, Zunica G. Angular Analysis of D^{0}→π^{+}π^{-}μ^{+}μ^{-} and D^{0}→K^{+}K^{-}μ^{+}μ^{-} Decays and Search for CP Violation. PHYSICAL REVIEW LETTERS 2022; 128:221801. [PMID: 35714260 DOI: 10.1103/physrevlett.128.221801] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/05/2021] [Accepted: 05/02/2022] [Indexed: 06/15/2023]
Abstract
The first full angular analysis and an updated measurement of the decay-rate CP asymmetry of the D^{0}→π^{+}π^{-}μ^{+}μ^{-} and D^{0}→K^{+}K^{-}μ^{+}μ^{-} decays are reported. The analysis uses proton-proton collision data collected with the LHCb detector at center-of-mass energies of 7, 8, and 13 TeV. The dataset corresponds to an integrated luminosity of 9 fb^{-1}. The full set of CP -averaged angular observables and their CP asymmetries are measured as a function of the dimuon invariant mass. The results are consistent with expectations from the standard model and with CP symmetry.
Collapse
|
122
|
Zeng X, Liu Y, Hu J, Li J, Wang Y, Zhao D, Wu L, Xiao Z, Li Z, Xu J, Meerwein S, Xie Y, Liang P. AB0392 EFFICACY AND SAFETY OF UPADACITINIB IN A CHINESE SUBGROUP OF PATIENTS WITH RHEUMATOID ARTHRITIS AND INADEQUATE RESPONSE TO CONVENTIONAL SYNTHETIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.1119] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BackgroundUpadacitinib (UPA) was effective in global Phase 3 trials in rheumatoid arthritis (RA) patients (pts) with inadequate response (IR) to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs).ObjectivesTo assess the efficacy and safety of UPA in csDMARD-IR pts with RA in Chinese subgroup from a Phase 3, randomized, double-blind, placebo (PBO)-controlled study (NCT02955212) 1.MethodsPts were randomized to 12 weeks of blinded treatment with UPA 15 mg once daily (QD) or PBO, in combination with csDMARDs. Primary and secondary endpoints were analyzed in a Chinese subgroup, including American College of Rheumatology criteria (ACR) responses, remission and low disease activity measures. Safety was analyzed for pts who received ≥1 dose of study drug.Results228 Chinese pts (67.5% of overall trial population) were randomized and took at least one dose of study drug. Baseline characteristics were generally balanced between UPA and PBO. 46% and 35.1% used methotrexate (MTX) alone as concomitant csDMARD in UPA and PBO group, respectively. 38.9% in UPA and 43.0% in PBO group used concomitant csDMARDs other than MTX and 15.0% and 21.9% respectively used a combination. At week 12, more Chinese pts receiving UPA achieved the primary endpoint of ACR20 compared with PBO (71.9% vs 31.6%, nominal p<0.001). UPA also showed greater improvements in all secondary endpoints vs PBO at Week 12 (Table 1), including ACR50 and ACR70, mean change in Disease Activity Score in 28 joints using C-reactive protein (DAS28-CRP), Health Assessment Questionnaire-Disability Index (HAQ-DI), Short-Form 36-item Health Survey-Physical Component Summary (SF-36 PCS), as well as proportion of pts achieving low disease activity based on DAS28-CRP ≤3.2 and Clinical Disease Activity Index (CDAI) ≤10, and clinical remission based on DAS28-CRP <2.6. Onset of response was rapid with more pts receiving UPA achieving ACR20 by Week 1 versus PBO (25.4% vs 5.3%, nominal p<0.001). Through Week 12 treatment-emergent adverse events (TEAEs) occurred in 57.9% of pts on UPA and 49.1% on PBO. The rate of pts with serious AEs (SAEs) was numerically higher with UPA than with PBO (6.1% vs 4.4%). TEAEs reported in ≥ 3% of subjects and with a higher rate on UPA vs. PBO were: upper respiratory tract infection, alanine aminotransferase increased, aspartate aminotransferase increased, hypertension, diarrhea, and leukopenia. Overall safety was consistent with the trial population1 and similar with the reported safety profile of the global clinical program2.Table 1.Summary of Efficacy Endpoint Results at Week 12 in Chinese SubgroupEndpoint aUPA 15mg (N=114)PBO (N=114)Primary endpointACR20, %71.9***31.6Secondary endpointsΔ DAS28-CRP-2.42***-0.75Δ HAQ-DI-0.55***-0.11Δ SF-36 PCS7.63 b***2.94 cDAS28-CRP ≤3.2, %46.5***9.6DAS28-CRP <2.6, %28.1***1.8CDAI ≤10, %33.3***7.0ACR50, %39.5***7.0ACR70, %16.7***2.6ACR20 at Week 1, %25.4***5.3***Nominal p<0.001 vs PBOaNon-responder imputation for binary endpoints; ANCOVA with multiple imputation for DAS28(CRP) and HAQ-DI; mixed model repeated measures for other continuous endpoints. Δ: mean change from baselinebN=106cN=104ConclusionUPA demonstrated clinical and functional improvement in Chinese csDMARD-IR RA pts. The safety of UPA was comparable with the overall study population and with the safety seen in the global Phase 3 program.References[1]Zeng X, Zhao D, Radominski SC, et al. Int J Rheum Dis. 2021;24:1530–1539.[2]Cohen SB, van Vollenhoven RF, Winthrop KL, et al. Ann Rheum Dis 2021;80:304–311.AcknowledgementsAbbVie funded this study; contributed to its design; participated in data collection, analysis, and interpretation of the data; and in the writing, review, and approval of the abstract. No honoraria or payments were made for authorship.Disclosure of InterestsXiaofeng Zeng: None declared, Yi Liu: None declared, Jiankang Hu: None declared, Jingyang Li: None declared, Yongfu Wang: None declared, Dongbao Zhao: None declared, Lijun Wu: None declared, Zhengyu Xiao: None declared, ZHIJUN LI: None declared, Jian Xu: None declared, Sebastian Meerwein Shareholder of: may own AbbVie stock or options, Employee of: AbbVie employee, Yunxia Xie Shareholder of: may own AbbVie stock or options, Employee of: AbbVie employee, Peiwen Liang Employee of: AbbVie
Collapse
|
123
|
Albadawi H, Altun I, Zhang Z, Hu J, Oklu R. Abstract No. 296 Bioengineered hydrogel with Tantalum Microparticles for vascular embolization. J Vasc Interv Radiol 2022. [DOI: 10.1016/j.jvir.2022.03.377] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open
|
124
|
Albadawi H, Hu J, Altun I, Zhang Z, Oklu R. Abstract No. 294 Cardiac tissue derived biomaterial for permanent arterial embolization. J Vasc Interv Radiol 2022. [DOI: 10.1016/j.jvir.2022.03.375] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open
|
125
|
Kay J, Zeng X, Chen L, Tang K, Shi G, Liu L, Wu L, Liu Y, Hu J, Liu S, Yi Z, Kim SH, Bae Y, Suh J, Rhee S, Lee S, Hwang C. AB0339 EFFICACY, PHARMACOKINETICS AND SAFETY BETWEEN CT-P13 AND CHINA-APPROVED INFLIXIMAB: 54 WEEK RESULT FROM A PHASE III RANDOMIZED CONTROLLED TRIAL IN CHINESE PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.1677] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BackgroundCT-P13 is an approved biosimilar to EU-approved and US-licensed Infliximab (INX) for the indications of rheumatoid arthritis (RA), adult and paediatric Crohn’s disease, adult and paediatric ulcerative colitis, ankylosing spondylitis, psoriatic arthritis and psoriasis.ObjectivesThe purpose of this study was to demonstrate equivalence of efficacy and compare PK and safety profiles of CT-P13 and China-approved INX.MethodsIn this randomized, double blinded, multicenter, parallel-group, phase III study, patients with active RA who had been responding inadequately to methotrexate for at least 3 months, were randomized to receive either CT-P13 or China-approved INX. Patients were treated with doses of 3 mg/kg at Weeks 0, 2, 6, then every 8 weeks up to Week 54. Prior to dosing at Week 30, patients randomized to China-approved INX underwent a second randomization either to continue China-approved INX or to switch to CT-P13 at Week 30. Results of patients who underwent transition to CT-P13 were included in the China-approved INX group. The primary efficacy endpoint was change in DAS28 (CRP) from baseline to Week 14, which was analyzed using an analysis of covariance. Equivalence was determined if the 90% CI for the estimate of treatment difference was entirely contained within the predefined equivalence margin of -0.6 to 0.6.Results270 patients were randomly assigned to 2 treatment groups in a 1:1 ratio (136 and 134 patients in the CT-P13 and China-approved INX groups, respectively) and 184 patients completed the study. The least square mean change (standard error) of DAS28 (CRP) from baseline to Week 14, -1.566 [0.1419] and -1.547 [0.1491], was similar between the CT-P13 and China-approved INX groups, respectively. The 90% CI for the estimate of treatment difference (-0.29, 0.25) was contained within the predefined equivalence margin, which demonstrated therapeutic equivalence between the groups. The mean actual values for DAS28 (CRP) decreased from baseline to Week 54 and were similar between the groups (Figure 1). Additional efficacy endpoints, including ACR responses (ACR20 at Week 14; 60.6%, 54.8% and at Week 54; 65.1%, 60.6% in the CT-P13 and China-approved INX groups, respectively), EULAR responses, CDAI, and SDAI, were similar between the groups, even after switching at Week 30. During the study, mean serum INX concentrations were similar between the groups. Between Weeks 14 and 22, mean (percent coefficient of variation) AUCτ were 11156333.615 (44.796) ng·h/mL and 11462884.280 (51.057) ng·h/mL, and Cmax,ss were 66577.2 (31.4) ng/mL and 66356.1 (21.0) ng/mL in the CT-P13 and China-approved INX groups, respectively, which were similar between the groups. Most treatment-emergent AEs were grade 1 or 2 in intensity. One malignancy was reported in the CT-P13 group and no deaths were reported. The proportions of patients with anti-drug antibodies were similar between the groups, even after switching at Week 30. The overall safety profile of CT-P13 was comparable to that of China-approved INX and no new safety issues were observed (Table 1).Table 1.Summary of Safety ResultsNumber of patients (%)CT-P13 (N=136)China-approved Infliximab (N=133)Treatment-emergent AEsTotal115 (84.6%)107 (80.5%)Related97 (71.3%)86 (64.7%)Treatment-emergent serious AEsTotal17 (12.5%)12 (9.0%)Related10 (7.4%)6 (4.5%)Infusion related reaction/ hypersensitivity/anaphylactic reactionsTotal(=Related)20 (14.7%)19 (14.3%)InfectionsTotal45 (33.1%)43 (32.3%)Related36 (26.5%)40 (30.1%)Note: Summary is presented for the safety population who received at least 1 dose (full or partial) of study drug.ConclusionThe study demonstrated that efficacy of CT-P13 is equivalent to that of China-approved INX. Also, the PK and safety profiles of CT-P13 were comparable to those of China-approved INX. No loss of efficacy or difference in safety or immunogenicity was observed after switching from China-approved INX to CT-P13 at Week 30.Disclosure of InterestsJonathan Kay Consultant of: Boehringer Ingelheim GmbH; Pfizer Inc.; Samsung Bioepis; Sandoz Inc., Grant/research support from: Pfizer Inc. (paid to UMass Chan Medical School), Xiaofeng Zeng Grant/research support from: Celltrion, Inc, Lin Chen Grant/research support from: Celltrion, Inc, Kaijiang Tang Grant/research support from: Celltrion, Inc, guixiu shi Grant/research support from: Celltrion, Inc, Lin Liu Grant/research support from: Celltrion, Inc, Lijun Wu Grant/research support from: Celltrion, Inc, Yi Liu Grant/research support from: Celltrion, Inc, Jiankang Hu Grant/research support from: Celltrion, Inc, Shengyun Liu Grant/research support from: Celltrion, Inc, Zheng Yi Grant/research support from: Celltrion, Inc, Sung Hyun Kim Employee of: Celltrion, Inc, YunJu Bae Employee of: Celltrion, Inc, JeeHye Suh Employee of: Celltrion, Inc, Seungjin Rhee Employee of: Celltrion, Inc, SeulGi Lee Employee of: Celltrion, Inc, Chankyoung Hwang Employee of: Celltrion, Inc
Collapse
|